ARTICLE | Clinical News
G17DT: Phase II data
June 14, 2004 7:00 AM UTC
In an international Phase II trial in 161 patients with refractory metastatic colorectal cancer receiving G17DT plus irinotecan, median survival was 229 days. Immune responders (62%) lived significant...